Physician profile
Megan Wright Mcclafferty
NPI 1225776784
$7,048.75
in general payments reported to CMS, 2019-2025
38 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $554 · 2023: $2,744 · 2024: $2,369 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,494.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $988.20 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $605.06 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $577.95 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $558.40 | 2022-2025 | Omnipod |
| Amgen INC. | $488.15 | 2023-2025 | Evenity, Prolia, Repatha |
| Mannkind Corporation | $363.21 | 2023-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $352.12 | 2022-2025 | Farxiga, Lokelma |
| Beta Bionics, INC. | $272.08 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.28 | 2023-2025 | Jardiance, Synjardy, Trijardy Xr |
| Bayer Healthcare Pharmaceuticals INC. | $249.86 | 2022-2025 | |
| Cequr Corporation | $211.14 | 2023-2025 | Cequr Simplicity |
| Abbvie INC. | $199.91 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $199.81 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $194.84 | 2023-2024 | |
| Medtronic, INC. | $156.20 | 2023-2025 | Minimed 780g |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $116.67 | 2023-2025 | Tirosint, Licart, Flector |
| Radius Health, INC. | $116.26 | 2022-2025 | Tymlos |
| Madrigal Pharmaceuticals | $96.32 | 2024-2025 | Resmetirom, Rezdiffra |
| Alexion Pharmaceuticals, INC. | $85.71 | 2022-2025 | Strensiq |
| Recordati_rare_diseases_inc. | $82.47 | 2023-2025 | Isturisa, Signifor Lar |
| Intra-Sana Laboratories | $79.77 | 2023-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Corcept Therapeutics | $76.60 | 2023-2024 | Korlym |
| Esperion Therapeutics, INC. | $75.23 | 2022-2024 | Nexletol |
| Ascensia Diabetes Care US INC. | $73.08 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.96 | 2022-2023 | Cycloset |
| Ascendis Pharma Endocrinology INC | $67.79 | 2023-2025 | Yorvipath |
| Antares Pharma, INC. | $64.35 | 2022-2025 | Xyosted |
| Amneal Pharmaceuticals LLC | $59.06 | 2023-2025 | Unithroid |
| Dexcom, INC. | $48.27 | 2023-2024 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $46.34 | 2025 | Twiist |
| Tolmar, INC. | $45.57 | 2023-2025 | Jatenzo |
| Rhythm Pharmaceuticals, INC. | $34.75 | 2025 | Imcivree |
| Amphastar Pharmaceuticals, INC. | $31.50 | 2024 | |
| Astellas Pharma US INC | $29.09 | 2025 | Veozah |
| Ultragenyx Pharmaceutical INC. | $22.21 | 2023 | |
| Kyowa Kirin, INC. | $21.36 | 2023 | Crysvita |
| Nevro Corp. | $19.85 | 2022 | |
| Tandem Diabetes Care, INC. | $15.33 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Mcclafferty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.